PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
Company profile
Ticker
PEPG
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PEPG stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
10-K/A
2023 FY
Annual report (amended)
29 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Mar 24
8-K
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
13 Mar 24
S-8
Registration of securities for employees
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
6 Mar 24
8-K
Other Events
4 Mar 24
8-K
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
20 Feb 24
424B5
Prospectus supplement for primary offering
7 Feb 24
Transcripts
Latest ownership filings
4/A
Change in insider ownership (amended)
9 Apr 24
SC 13G
Oxford Science Enterprises plc
9 Apr 24
144
Notice of proposed sale of securities
12 Mar 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
11 Mar 24
4
Niels Svenstrup
1 Mar 24
4
James G McArthur
1 Mar 24
4
Noel Donnelly
1 Mar 24
4
Michelle L Mellion
1 Mar 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
4
Peter Kolchinsky
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 131.04 mm | 131.04 mm | 131.04 mm | 131.04 mm | 131.04 mm | 131.04 mm |
Cash burn (monthly) | 5.83 mm | 5.52 mm | 8.26 mm | 6.76 mm | 5.49 mm | 5.25 mm |
Cash used (since last report) | 38.94 mm | 36.88 mm | 55.18 mm | 45.18 mm | 36.69 mm | 35.05 mm |
Cash remaining | 92.10 mm | 94.16 mm | 75.86 mm | 85.86 mm | 94.35 mm | 95.99 mm |
Runway (months of cash) | 15.8 | 17.1 | 9.2 | 12.7 | 17.2 | 18.3 |
Institutional ownership, Q2 2023
59.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 46 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 11 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 153.45 bn |
Total shares | 19.29 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 8.13 mm | $72.70 bn |
FMR | 2.74 mm | $24.53 bn |
Viking Global Investors | 1.48 mm | $13.25 bn |
Qatar Investment Authority | 1.24 mm | $0.00 |
Flynn James E | 953.63 k | $0.00 |
BLK Blackrock | 840.65 k | $7.52 bn |
Laurion Capital Management | 664.52 k | $5.94 bn |
Samsara BioCapital | 651.05 k | $5.82 bn |
Adage Capital Partners GP, L.L.C. | 575.00 k | $5.14 bn |
Vanguard | 501.32 k | $4.48 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Michelle L Mellion | Stock Option Common Stock | Grant | Acquire A | No | No | 16.62 | 83,000 | 1.38 mm | 83,000 |
1 Mar 24 | Noel Donnelly | Stock Option Common Stock | Grant | Acquire A | No | No | 16.62 | 144,000 | 2.39 mm | 144,000 |
1 Mar 24 | James G McArthur | Stock Option Common Stock | Grant | Acquire A | No | No | 16.62 | 300,000 | 4.99 mm | 300,000 |
1 Mar 24 | Niels Svenstrup | Stock Option Common Stock | Grant | Acquire A | No | No | 16.62 | 83,000 | 1.38 mm | 83,000 |
9 Feb 24 | Ra Capital Management | Common Stock | Buy | Acquire P | Yes | No | 10.64 | 2,557,593 | 27.21 mm | 9,179,273 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Apr 24
Insiders Buying GameStop And 2 Other Stocks
10 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
7 Mar 24
PepGen Reported March 6 Q4 2023 GAAP EPS $(0.810) Beats $(1.010) Estimate
7 Mar 24
Wedbush Maintains Outperform on PepGen, Lowers Price Target to $20
7 Mar 24
Press releases
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
13 Mar 24
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
6 Mar 24
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
7 Feb 24